WASHINGTON, June 9 (UPI) -- The U.S. Food and Drug Administration announced the addition of a boxed warning for Regranex (becaplermin) because of an increased risk of cancer mortality. The warning ...

Smith & Nephew (LSE:SN, NYSE:SNN), the global medical technology business, today announces the introduction of Regranex360™, a comprehensive new program to support patients in the U.S. using REGRANEX™ ...

WASHINGTON The Food and Drug Administration has added a black-box warning to Johnson & Johnson’s foot ulcer medication Regranex, warning that when used in large amounts, it could heighten the risk of ...

Healthpoint Biotherapeutics announced that it has acquired Regranex Gel, along with the corresponding intellectual property (including patents), from Systagenix. Terms of the deal were not disclosed. ...

REGRANEX Gel is the first and only FDA-approved available platelet-derived growth factor (:PDGF) therapy that can be used for the treatment of lower extremity diabetic neuropathic ulcers. Regranex360 ...

WASHINGTON, June 6 (Reuters) - Johnson & Johnson has added a strong "black box" warning about the risk of dying from cancer to the prescribing instructions for the company's Regranex diabetic foot gel ...

Somerville, New Jersey Tuesday, June 10, 2008, 08:00 Hrs [IST] Ethicon, Inc. announces revised labeling for Regranex Gel, a topical formulation of recombinant human platelet-derived growth factor ...

Johnson & Johnson (NYSE:JNJ) will be selling a little less of its foot ulcer gel Regranex -- at least to the patients who used it the most. (Foot ulcers are slowly healing foot wounds, often suffered ...

Regranex is a topical recombinant human platelet-derived growth factor indicated as an adjunct to the treatment of lower extremity diabetic neuropathic ulcers.

The FDA is investigating the possibility of an increased risk of cancer in diabetic patients who apply Regranex (becaplermin gel, from Ortho-McNeil) directly to foot and leg ulcers. In a recent study ...

Adocia has announced positive results from its Phase II clinical trial evaluating the safety and efficacy of BioChaperone® combined with PDGF-BB for the treatment of diabetic foot ulcer. This product ...

FORT WORTH, Texas, June 2, 2011 /PRNewswire/ -- Healthpoint Biotherapeutics today announced that it has acquired Regranex® Gel, along with the corresponding intellectual property (including patents), ...